A Personalized mRNA Vaccine Cut the Risk of Melanoma Returning

A cancer vaccine manufactured separately for each patient has delivered its first detailed Phase 3 result. In the INTerpath-001 trial, adding Moderna and Merck's intismeran autogene to Keytruda reduced the combined risk of melanoma recurrence or death by 42% compared with Keytruda alone after surgery.

The result behind the 42%

Participants with completely resected stage IIB to IV melanoma were randomly assigned in a 2:1 ratio. The experimental group received intismeran plus Keytruda, while the control group received a placebo plus Keytruda. After a median follow-up of 24.6 months, the hazard ratio for recurrence or death was 0.58, corresponding to a 42% relative reduction.

Key Number: 82.2% of patients assigned to intismeran plus Keytruda were alive without a recurrence at two years, compared with 70.0% on Keytruda alone.

The combination also reduced the risk of distant metastasis or death by 38%. Treatment-related adverse events occurred in 95.8% of the combination group and 90.0% of the control group. Serious grade 3 to 5 treatment-related events were similar, at 14.2% versus 13.4%. Fever, injection-site pain and fatigue were the most common reactions reported with the vaccine combination.

A vaccine designed from one tumor

Intismeran is not a preventive vaccine and it is not one identical product supplied to every patient. Researchers sequence removed tumor tissue and normal blood, identify mutations unique to the cancer, and select up to 34 corresponding neoantigens. A custom mRNA sequence instructs the patient's cells to produce those molecular targets so immune cells can learn what to attack if cancer cells remain or return.

Keytruda, or pembrolizumab, blocks the PD-1 immune checkpoint that tumors can exploit to suppress T cells. The vaccine supplies individualized targets while the checkpoint inhibitor helps the immune system act on them. NewTqnia has previously covered both a failed mRNA cancer-vaccine trial and preclinical mRNA delivery into tumor-supporting immune cells, illustrating why a randomized Phase 3 outcome is materially different from platform promise or animal evidence.

Why the timing matters

Moderna and Merck had announced in August that the study met its main endpoints, but they did not provide the detailed effect sizes. The October 22 release supplies the prespecified analysis, two-year rates, confidence intervals and safety totals. The findings were scheduled for presentation at the 2026 European Society for Medical Oncology congress and have been accepted for publication in The New England Journal of Medicine.

The trial enrolled 1,137 patients across an international network. Each participant's melanoma had already been surgically removed, so the goal was to prevent recurrence rather than shrink an existing tumor. The custom-vaccine regimen consisted of up to nine doses given every three weeks, alongside about one year of Keytruda.

What happens next

Moderna and Merck say they are discussing the results with regulators. The ongoing trial will continue tracking survival and longer-term safety. Approval would make manufacturing reliability and equitable access central questions, while trials in lung, kidney and bladder cancer will test whether this personalized approach works beyond melanoma.